论文部分内容阅读
目的探讨门冬氨酸鸟氨酸治疗慢性重型肝炎的临床疗效。方法 42例慢性重型肝炎给予注射用门冬氨酸鸟氨酸及其他综合基础治疗。结果治疗前后肝功能治疗组与对照组比较有明显改善(P﹤0.05);治疗组总有效率(78.6%)与对照组(59.5%)之间的差异有统计学意义(P﹤0.05);治疗组存活率(85.7%)与对照组(66.7%)比较亦呈显著差异(P﹤0.05)。结论注射用门冬氨酸鸟氨酸对治疗慢性重型肝炎的肝功能有明显的疗效,并且能够对肝性脑病起预防和治疗作用,在临床应用上安全有保证。
Objective To investigate the clinical efficacy of ornithine ornithine in the treatment of chronic severe hepatitis. Methods 42 cases of chronic severe hepatitis were given aspartate ornithine for injection and other basic treatment. Results Before and after treatment, the liver function therapy group was significantly improved compared with the control group (P <0.05). The difference between the total effective rate (78.6%) and the control group (59.5%) in the treatment group was statistically significant (P <0.05). The survival rate in the treatment group (85.7%) was also significantly different from that in the control group (66.7%) (P <0.05). Conclusion Aspartate ornithine for injection has obvious curative effect on liver function in treating chronic severe hepatitis, and can prevent and treat hepatic encephalopathy and is safe in clinical application.